Initiative Makes Stem Cell Lines Available for Research Worldwide

Initiative Makes Stem Cell Lines Available for Research Worldwide

A number of stem cell lines developed to better understand how certain genetic factors might contribute to amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases is now available to scientists worldwide. The cell lines were engineered by researchers at the National Institutes of Health Center for Alzheimer’s and Related…

Radicava Seen in Real-world Study to Prolong Survival With ALS

Real-world use of Radicava (edaravone) significantly prolongs survival in amyotrophic lateral sclerosis (ALS) patients, with people in the U.S. on the therapy living about six months longer than those not on this treatment, an analysis of Radicava’s use in clinical settings reported. The estimated probability of survival was greater…

ALS Link With Specific STMN2 Gene Mutation Challenged in Study

A mutation in the STMN2 gene that consists of an excessive repeat of two nucleotides, the building blocks of DNA, is not associated with the greater risk of amyotrophic lateral sclerosis (ALS), a new study reported. Its findings contradict previous research suggesting a link between this particular mutation and ALS. “Although the…

‘Life Is Pain’: Living Day by Day With ALS

Months after my husband, Todd, was diagnosed with ALS, our church’s worship leader asked us to participate in a Sunday morning service with “Cardboard Testimonies.” We watched an example on YouTube in which music played while people stood in front of the congregation and shared their stories. Presenters didn’t…

Kadimastem Secures US Patent for Cell Therapy AstroRx

Kadimastem has received a U.S. patent covering its investigational cell therapy AstroRx for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The patent, granted by the U.S. Patent and Trademark Office, supports an upcoming Phase 2a clinical trial that’s planned to start in the U.S. next year.